{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T07:06:35Z","timestamp":1764313595415,"version":"3.46.0"},"reference-count":56,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tierarztl Prax Ausg K Kleintiere Heimtiere"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Oclacitinib (Apoquel, Zoetis) ist aktuell der einzige in der EU f\u00fcr die\n                    Veterin\u00e4rmedizin zugelassene Januskinase (JAK)-Inhibitor. Das Medikament ist\n                    zugelassen f\u00fcr die Behandlung von atopischer Dermatitis und allergischem\n                    Juckreiz des Hundes. Hierf\u00fcr wird es bereits seit \u00fcber 10 Jahren sicher und\n                    erfolgreich eingesetzt. Weiterhin sind bereits mehrere Fallberichte publiziert,\n                    welche nach Aussch\u00f6pfung der zugelassenen Medikamente von einem erfolgreichen\n                    Off-Label-Einsatz von Oclacitinib insbesondere bei T-Zell-mediierten\n                    Krankheitsbildern berichten.<\/jats:p>\n                  <jats:p>Oclacitinib ist nur f\u00fcr Hunde zugelassen. Von einem Einsatz bei Katzen wird\n                    abgeraten, da hierf\u00fcr nicht gen\u00fcgend Daten aus klinischen Studien vorliegen. Es\n                    ist jedoch bekannt, dass diese eine h\u00f6here Dosierung ben\u00f6tigen und die\n                    therapeutische Breite geringer ist als bei Hunden. In diesem \u00dcbersichtsartikel\n                    wird eine Zusammenfassung \u00fcber Studien zur Anwendung von Oclacitinib bei Hunden\n                    mit atopischer Dermatitis sowie ein Ausblick zur Verabreichung bei Katzen\n                    gegeben. Weiterhin wird eine \u00dcbersicht zur erfolgreichen Anwendung von\n                    Oclacitinib bei anderen immunmediierten Krankheiten vermittelt.<\/jats:p>","DOI":"10.1055\/a-2546-1573","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T18:52:05Z","timestamp":1749840725000},"page":"146-158","source":"Crossref","is-referenced-by-count":0,"title":["Oclacitinib \u2013 Januskinase-Hemmung in der\n                    Veterin\u00e4rdermatologie"],"prefix":"10.1055","volume":"53","author":[{"given":"Paulina J.C.","family":"Popp","sequence":"additional","affiliation":[{"name":"Kleintierklinik, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf S.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Kleintierklinik, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5326\/JAAHA-MS-7396","article-title":"2023 AAHA Management of Allergic Skin Diseases in Dogs and Cats Guidelines","volume":"59","author":"J Miller","year":"2023","journal-title":"J Am Anim Hosp Assoc"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/vetsci9040149","article-title":"Clinical Guidelines for the Use of Antipruritic Drugs in the Control of the Most\n                    Frequent Pruritic Skin Diseases in Dogs","volume":"9","author":"V Bruet","year":"2022","journal-title":"Vet Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1111\/vde.12088","article-title":"A blinded, randomized, placebo-controlled trial of the efficacy and safety of\n                    the Janus kinase inhibitor oclacitinib (Apoquel(R)) in client-owned dogs with\n                    atopic dermatitis","volume":"24","author":"S B Cosgrove","year":"2013","journal-title":"Vet Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"R Morris","year":"2018","journal-title":"Protein Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"W Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic Mechanisms of JAK Inhibition","volume":"31","author":"C M Lin","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"K Yamaoka","year":"2004","journal-title":"Genome Biol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"K Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus kinases to jakinibs: from basic insights to clinical practice","volume":"58","author":"M Gadina","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1111\/ddg.14921","article-title":"Pharmacology of inhibitors of Janus kinases - Part 1: Pharmacokinetics","volume":"20","author":"A Eichner","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL((R))) is a novel Janus kinase inhibitor with activity\n                    against cytokines involved in allergy","volume":"37","author":"A J Gonzales","year":"2014","journal-title":"J Vet Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/jvp.12087","article-title":"The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the\n                    dog","volume":"37","author":"W T Collard","year":"2014","journal-title":"J Vet Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1365-3164.2012.01098.x","article-title":"Interleukin-31: its role in canine pruritus and naturally occurring canine\n                    atopic dermatitis","volume":"24","author":"A J Gonzales","year":"2013","journal-title":"Vet Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/vde.12047","article-title":"Efficacy and safety of oclacitinib for the control of pruritus and associated\n                    skin lesions in dogs with canine allergic dermatitis","volume":"24","author":"S B Cosgrove","year":"2013","journal-title":"Vet Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1111\/vde.12194","article-title":"Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin\n                    disease: safety, efficacy and quality of life","volume":"26","author":"S B Cosgrove","year":"2015","journal-title":"Vet Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/vde.13053","article-title":"Prolonged twice-daily administration of oclacitinib for the control of canine\n                    atopic dermatitis: a retrospective study of 53 client-owned atopic dogs","volume":"33","author":"D Denti","year":"2022","journal-title":"Vet Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e586","DOI":"10.1111\/vde.12166","article-title":"Efficacy of oclacitinib (Apoquel(R)) compared with prednisolone for the control\n                    of pruritus and clinical signs associated with allergic dermatitis in\n                    client-owned dogs in Australia","volume":"25","author":"C Gadeyne","year":"2014","journal-title":"Vet Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1111\/vde.12186","article-title":"A blinded, randomized clinical trial comparing the efficacy and safety of\n                    oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned\n                    dogs","volume":"26","author":"P R Little","year":"2015","journal-title":"Vet Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/vde.12450","article-title":"The frequency of urinary tract infection and subclinical bacteriuria in dogs\n                    with allergic dermatitis treated with oclacitinib: a prospective study","volume":"28","author":"A C Simpson","year":"2017","journal-title":"Vet Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/art.38894","article-title":"Lipid profile changes in patients with chronic inflammatory arthritis treated\n                    with biologic agents and tofacitinib in randomized clinical trials: a systematic\n                    review and meta-analysis","volume":"67","author":"A Souto","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/vde.12452","article-title":"A retrospective study comparing the incidence of cutaneous histiocytoma\n                    development in atopic dogs treated with oclacitinib and ciclosporin","volume":"28","year":"2017","journal-title":"Veterinary Dermatology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2460\/javma.257.5.507","article-title":"Age- and breed-matched retrospective cohort study of malignancies and benign\n                    skin masses in 660 dogs with allergic dermatitis treated long-term with versus\n                    without oclacitinib","volume":"257","author":"B A Lancellotti","year":"2020","journal-title":"J Am Vet Med Assoc"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/vde.12698","article-title":"Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation\n                    and cytokine production","volume":"30","author":"F Banovic","year":"2019","journal-title":"Vet Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.2460\/javma.22.12.0570","article-title":"Oclacitinib 10 years later: lessons learned and directions for the future","volume":"261","author":"R Marsella","year":"2023","journal-title":"J Am Vet Med Assoc"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/vde.12793","article-title":"The usefulness of short-course prednisolone during the initial phase of an\n                    elimination diet trial in dogs with food-induced atopic dermatitis","volume":"30","author":"C Favrot","year":"2019","journal-title":"Vet Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/vde.12940","article-title":"Sensitivity and specificity of a shortened elimination diet protocol for the\n                    diagnosis of food-induced atopic dermatitis (FIAD)","volume":"32","author":"N Fischer","year":"2021","journal-title":"Vet Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s0301-0546(05)73248-1","article-title":"Rebound phenomenon to systemic corticosteroid in atopic dermatitis","volume":"33","author":"W C Forte","year":"2005","journal-title":"Allergol Immunopathol (Madr)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/vde.13134","article-title":"A randomised controlled trial testing the rebound-preventing benefit of four\n                    days of prednisolone during the induction of oclacitinib therapy in dogs with\n                    atopic dermatitis","volume":"34","author":"T Olivry","year":"2023","journal-title":"Vet Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejphar.2016.11.020","article-title":"Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1\n                    inhibitor oclacitinib","volume":"794","author":"T Fukuyama","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/vde.13193","article-title":"A randomised, double-blinded, controlled trial to determine the efficacy of\n                    combined therapy of oclacitinib and marine oil extract PCSO-524 in dogs with\n                    atopic dermatitis","volume":"34","author":"T Nishiyama","year":"2023","journal-title":"Vet Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/vde.12218","article-title":"Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis:\n                    results of a small prospective pilot study of client-owned cats","volume":"26","author":"C Ortalda","year":"2015","journal-title":"Vet Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/vde.12819","article-title":"A pharmacokinetic study of oclacitinib maleate in six cats","volume":"31","author":"L Ferrer","year":"2020","journal-title":"Vet Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1177\/1098612X211048458","article-title":"Efficacy of oclacitinib for the control of feline atopic skin syndrome:\n                    correlating plasma concentrations with clinical response","volume":"24","author":"I Carrasco","year":"2022","journal-title":"J Feline Med Surg"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12917-019-1893-x","article-title":"A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in\n                    cats","volume":"15","author":"N L Lopes","year":"2019","journal-title":"BMC Vet Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/vde.13097","article-title":"Fatal disseminated toxoplasmosis in a feline immunodeficiency virus-positive cat\n                    receiving oclacitinib for feline atopic skin syndrome","volume":"33","author":"A Moore","year":"2022","journal-title":"Vet Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2460\/ajvr.76.4.351","article-title":"Effect of oral administration of cyclosporine on Toxoplasma gondii infection\n                    status of cats","volume":"76","author":"M R Lappin","year":"2015","journal-title":"Am J Vet Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1365-3164.2004.00360.x","article-title":"Pemphigus: current therapy","volume":"15","author":"W S Rosenkrantz","year":"2004","journal-title":"Vet Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5326\/0420189","article-title":"Pemphigus foliaceus in 91 dogs","volume":"42","author":"R S Mueller","year":"2006","journal-title":"J Am Anim Hosp Assoc"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12917-018-1446-8","article-title":"Cutaneous lupus erythematosus in dogs: a comprehensive review","volume":"14","author":"T Olivry","year":"2018","journal-title":"BMC Vet Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-3164.2006.00540.x","article-title":"A review of autoimmune skin diseases in domestic animals: I \u2013 superficial\n                    pemphigus","volume":"17","author":"T Olivry","year":"2006","journal-title":"Vet Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/vde.13203","article-title":"The use of oclacitinib compared to azathioprine in the management of canine\n                    pemphigus foliaceus: A retrospective analysis","volume":"34","author":"A Hernandez-Bures","year":"2023","journal-title":"Vet Dermatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/vde.12949","article-title":"Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus","volume":"32","author":"I Carrasco","year":"2021","journal-title":"Vet Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12917-023-03597-1","article-title":"Spontaneous autoimmune subepidermal blistering diseases in animals: a\n                    comprehensive review","volume":"19","author":"P Bizikova","year":"2023","journal-title":"BMC Vet Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/vde.12458","article-title":"A case of presumed autoimmune subepidermal blistering dermatosis treated with\n                    oclacitinib","volume":"28","author":"E Aymeric","year":"2017","journal-title":"Vet Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/vde.13128","article-title":"Effective treatment of canine chronic cutaneous lupus erythematosus variants\n                    with oclacitinib: Seven cases","volume":"34","author":"R G Harvey","year":"2023","journal-title":"Vet Dermatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/vde.12852","article-title":"Rapid response of hyperkeratotic erythema multiforme to oclacitinib in two\n                    dogs","volume":"31","author":"E J High","year":"2020","journal-title":"Vet Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.cvsm.2018.08.006","article-title":"Canine Perianal Fistulas: Clinical Presentation, Pathogenesis, and\n                    Management","volume":"49","author":"C L Cain","year":"2019","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/vde.13171","article-title":"Successful treatment of perianal fistulas in two dogs with oclacitinib","volume":"34","author":"R Harvey","year":"2023","journal-title":"Vet Dermatol"},{"key":"ref50","first-page":"293","article-title":"Canine sebaceous adenitis","volume":"62","author":"C Pye","year":"2021","journal-title":"Can Vet J"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/vde.13216","article-title":"Successful treatment of sebaceous adenitis with oclacitinib and low-dose\n                    prednisolone in a dog","volume":"35","author":"M Perez-Aranda","year":"2024","journal-title":"Vet Dermatol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/vde.12976","article-title":"Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib:\n                    a case report","volume":"32","author":"J Aslan","year":"2021","journal-title":"Vet Dermatol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/vde.12743","article-title":"The role of oclacitinib in the management of ischaemic dermatopathy in four\n                    dogs","volume":"30","author":"B J Levy","year":"2019","journal-title":"Vet Dermatol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/vde.12992","article-title":"Ear tip ulcerative dermatitis treated with oclacitinib in 25 dogs: a\n                    retrospective case series","volume":"32","author":"S Colombo","year":"2021","journal-title":"Vet Dermatol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/vde.13269","article-title":"Oclacitinib therapy in two cats with refractory proliferative and necrotising\n                    otitis externa","author":"T Chan","year":"2024","journal-title":"Vet Dermatol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1365-3164.2007.00614.x","article-title":"Proliferative and necrotizing otitis externa in four cats","volume":"18","author":"E A Mauldin","year":"2007","journal-title":"Vet Dermatol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/vde.12968","article-title":"Extra-auricular lesions of proliferative and necrotizing otitis externa in three\n                    kittens","volume":"32","author":"P Panzuti","year":"2021","journal-title":"Vet Dermatol"}],"container-title":["Tier\u00e4rztliche Praxis Ausgabe K: Kleintiere \/ Heimtiere"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2546-1573.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T07:02:01Z","timestamp":1764313321000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2546-1573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":56,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,6,13]]},"published-print":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2546-1573","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1434-1239","2567-5842"],"issn-type":[{"type":"print","value":"1434-1239"},{"type":"electronic","value":"2567-5842"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}